<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02317536</url>
  </required_header>
  <id_info>
    <org_study_id>15CAHL</org_study_id>
    <nct_id>NCT02317536</nct_id>
  </id_info>
  <brief_title>A Pilot Clinical Trial on the Efficacy of Two Carnitine-Based Products on Muscle Function in Healthy Older Adults</brief_title>
  <acronym>15CAHL</acronym>
  <official_title>A Randomized Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Relative Efficacy of Two Carnitine-Based Products Purported to Promote Muscle Anabolism in Healthy Older Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lonza Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates two L-Carnitine-based products on muscle function in healthy older
      adults (55 to 70 years old). These products are suspected to improve muscle function and
      possibly promote building of muscle mass. One third of the subjects will be on Carnipure
      Product 1, one third will be on Carnipure Product 2 and one third will be on placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Muscle Function Composite Endpoint from Baseline to Day 57 of subjects administer Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>A composite endpoint determined by multiplying the values of Lean Body Mass (as assessed by DXA, kg), and functional muscle strength (as assessed by 6 Minute Walk Test, metres; Lower Body Dynamometry, kg; Upper Body Dynamometry, kg). Percent change from baseline to day 57 will be derived.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional lower body strength will be determined using a hand-held dynamometer to measure leg extension resistance (kg of resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional upper body strength from baseline to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional upper body strength will be determined using a grip strength dynamometer to measure grip strength resistance (kg of resistance).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional lower body strength will be assessed using the 6 Minute Walk Test to determine the distance walked over 6 minutes (metres).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life questionnaire score from baseline to day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Assessed using the RAND SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lean Body Mass from baseline to day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Lean Body Mass measured by DXA scan</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in muscle metabolism from baseline to day 57 in subjects administered Carnipure Product 2 versus Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Assessed by laboratory analysis of muscle biopsy samples collected at baseline (pre-strength testing) and Day 57 (pre and post-strength testing)</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Muscle Function Composite Endpoint from Baseline to Day 57 of subjects administer Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>A composite endpoint determined by multiplying the values of Lean Body Mass (as assessed by DXA, kg), and functional muscle strength (as assessed by 6 Minute Walk Test, metres; Lower Body Dynamometry, kg; Upper Body Dynamometry, kg). Percent change from baseline to day 57 will be derived.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent Change in Muscle Function Composite Endpoint from Baseline to Day 57 of subjects administer Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>A composite endpoint determined by multiplying the values of Lean Body Mass (as assessed by DXA, kg), and functional muscle strength (as assessed by 6 Minute Walk Test, metres; Lower Body Dynamometry, kg; Upper Body Dynamometry, kg). Percent change from baseline to day 57 will be derived.</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Lean Body Mass from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Lean Body Mass measured by DXA scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Lean Body Mass from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Lean Body Mass measured by DXA scan</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Baseline to Day 57</time_frame>
    <description>Functional lower body strength will be determined using a hand-held dynamometer to measure leg extension resistance (kg of resistance).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional lower body strength will be determined using a hand-held dynamometer to measure leg extension resistance (kg of resistance).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional upper body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional upper body strength will be determined using a grip strength dynamometer to measure grip strength resistance (kg of resistance).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional upper body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional upper body strength will be determined using a grip strength dynamometer to measure grip strength resistance (kg of resistance).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional lower body strength will be assessed using the 6 Minute Walk Test to determine the distance walked over 6 minutes (metres).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Functional lower body strength will be assessed using the 6 Minute Walk Test to determine the distance walked over 6 minutes (metres).</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Quality of Life questionnaire score from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Assessed using the RAND SF-36 questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Quality of Life questionnaire score from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Assessed using the RAND SF-36 questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in muscle metabolism from baseline to day 57 in subjects administered Carnipure Product 1 versus Placebo</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Assessed by laboratory analysis of muscle biopsy samples collected at baseline (pre-strength testing) and Day 57 (pre and post-strength testing)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in muscle metabolism from baseline to day 57 in subjects administered Carnipure Product 1 versus Carnipure Product 2</measure>
    <time_frame>Baseline and Day 57</time_frame>
    <description>Assessed by laboratory analysis of muscle biopsy samples collected at baseline (pre-strength testing) and Day 57 (pre and post-strength testing)</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs from baseline to day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Screening to Day 57</time_frame>
    <description>Blood pressure, heart rate, BMI, electrocardiogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Screening to Day 57</time_frame>
    <description>Blood pressure, heart rate, BMI, electrocardiogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in vital signs from screening to day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Screening to Day 57</time_frame>
    <description>Blood pressure, heart rate, BMI, electrocardiogram</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in hematology and clinical chemistry from screening to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>Screening and Day 57</time_frame>
    <description>CBC, electrolytes, glucose, creatinine, AST, ALT, GGT, bilirubin</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in hematology and clinical chemistry from screening to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>Screening and Day 57</time_frame>
    <description>CBC, electrolytes, glucose, creatinine, AST, ALT, GGT, bilirubin</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in hematology and clinical chemistry from screening to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>Screening and Day 57</time_frame>
    <description>CBC, electrolytes, glucose, creatinine, AST, ALT, GGT, bilirubin</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events experienced in subjects administered Carnipure Product 2 versus those administered Placebo</measure>
    <time_frame>57 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events experienced in subjects administered Carnipure Product 1 versus those administered Placebo</measure>
    <time_frame>57 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of adverse events experienced in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2</measure>
    <time_frame>57 days</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Muscle Function</condition>
  <arm_group>
    <arm_group_label>Carnipure Product 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carnitine-based product 1, subjects will take one dose once daily for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnipure Product 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carnitine-based product 2, subjects will take one dose once daily for 56 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, subjects will take one dose once daily for 56 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carnipure Product 1</intervention_name>
    <arm_group_label>Carnipure Product 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Carnipure Product 2</intervention_name>
    <arm_group_label>Carnipure Product 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female adults, aged 55 to 70 years

          -  BMI of 21 kg/m2 to 33 kg/m2

          -  Subjects in good physical condition such that they can perform exercise testing
             safely, as determined by the Qualified Investigator based on medical history, physical
             examination, electrocardiogram and laboratory results

          -  Subjects who are sedentary and not currently engaging in any regular exercise.

          -  Subjects who agree to maintain their current level of activity and current dietary
             habits throughout the trial period.

          -  Subjects who have given voluntary, written, informed consent to participate in the
             study.

        Exclusion Criteria:

          -  Subjects who are smokers or have been a smoker within the past 1 year from screening.

          -  Subjects who are pregnant or breastfeeding

          -  Subjects who have experienced weight loss or gain of greater than 4.5 kg
             (approximately 10 lbs) within 3 months of randomization

          -  Subjects diagnosed with active heart disease

          -  Subjects with uncontrolled hypertension (â‰¥ 140 mmHg)

          -  Subjects with renal or hepatic impairment or disease

          -  Subjects with any major diseases of the gastrointestinal, pulmonary or endocrine
             systems

          -  Subjects with a history of seizures

          -  Subjects with Type I or Type II Diabetes

          -  Subjects with active cancer (excluding basal cell carcinoma)

          -  Subjects with neurological or significant psychiatric illnesses, including Parkinson's
             disease and bi-polar disorder

          -  Subjects with unstable thyroid disease

          -  Subjects who are immuno-compromised (HIV positive, on anti-rejection medication,
             rheumatoid arthritis)

          -  Subjects with metal fixation plates or screws from a previous surgery

          -  Subjects who are taking oral anticoagulants (blood thinners) such as warfarin
             (Coumadin) or Dabigatran (Pradaxa) or antiplatelet agents such as Clopidogrel (Plavix)

          -  Subjects who are regularly taking NSAID medications such as aspirin, must stop at
             least one week prior to the micro-needle muscle biopsy procedures.

          -  Subjects with a known allergy to anesthetic

          -  Subjects who currently experience any medical condition that interferes with the
             ability to undergo physical strength testing during the study

          -  Subjects currently taking NHPs must have been using their current dosing regimen for
             at least one month prior to baseline and must maintain their current dosing regimen
             throughout the trial and must not begin taking any new NHPs throughout the trial. If
             the subject wishes to stop taking the NHP prior to beginning the trial, they must do
             so at least 1 week prior to randomization.

          -  Subjects who use illicit drugs or have a history of alcohol or drug abuse within the
             past 6 months

          -  Subjects who currently consume greater than 2 standard alcoholic drinks per day.

          -  Subjects who have participated in a clinical research trial within 30 days prior to
             randomization.

          -  Subjects with an allergy or sensitivity to the investigational product ingredient.

          -  Subjects who are cognitively impaired and/or who are unable to give informed consent

          -  Subjects who have abnormal laboratory results or any other medical or psychological
             condition which, in the opinion of the Qualified Investigator, may adversely affect
             the subjects ability to complete the study or its measures or which may pose
             significant risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetyana Pelipyagina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2014</study_first_submitted>
  <study_first_submitted_qc>December 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2014</study_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Muscle function</keyword>
  <keyword>L-Carnitine</keyword>
  <keyword>Carnipure</keyword>
  <keyword>DXA</keyword>
  <keyword>anabolism</keyword>
  <keyword>6 minute walk</keyword>
  <keyword>dynamometry</keyword>
  <keyword>muscle biopsy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

